top of page
Search

New alarm over China's pharma power

snitzoid
6 hours ago
4 min read

These guys are turning out to be a royal pain in the ass!


I had Gemini provide some context below.


New alarm over China's pharma power

By Adriel Bettelheim, Axios News

Nov 19,2026

China is intensifying efforts to control the entire drug supply chain, putting the U.S. at risk of being cut off from future lifesaving treatments, the National Security Commission on Emerging Biotechnology warns in a new analysis out today.


Why it matters: Western drug giants have invested huge sums in Chinese biotechs to boost their product pipelines. But sharing capital and expertise could give Beijing more control over critical pharmaceutical technologies.


Concerns about the U.S. getting boxed out have intensified after the Chinese government proposed new restrictions last month on the export of certain technologies, including cell and gene therapy platforms.

Driving the news: Western drug giants are increasingly entering into licensing agreements with Chinese firms that redirect U.S. capital away from U.S. innovation and toward the Chinese pharmaceutical industry, the commission found in its analysis of 57 deals from the beginning of 2023 through last month.


The deals are being made earlier in the drug discovery process, allowing the Chinese partners to gain not just capital but know-how in developing and commercializing treatments.


This kind of knowledge transfer in automobiles, semiconductors and industrial chemicals gave Chinese industry a competitive edge and leverage to control global markets for the products, according to the commission, which was established by Congress to examine how emerging biotech intersects with national security.


"The end game is the same for the [Chinese Communist Party] in the pharmaceutical industry," the commission warns, saying the goal is increased U.S. dependence on Chinese innovation and enrichment of the Chinese pharmaceutical industry.

Between the lines: Drugmakers including AstraZeneca, Bristol Myers Squibb and Pfizer have been drawn by China's surge of investment in the life sciences and the promise of faster clinical trials and product approvals.


Typically a Chinese biotechnology company sells the license to develop or commercialize a treatment it developed to a multinational pharmaceutical company.


The Western companies see the arrangements as a way to outsource the burden of drug discovery and verify early results. But the commission found that the deals are increasingly based on preclinical data and that upfront payments are coming earlier in the R&D cycle.

The commission says this can result in a "flywheel effect" that sees royalties and equity in joint ventures flow back to China, fueling new research and infrastructure and attracting global talent.


Threat level: The concern is what happens if China scales up and corners a market, establishing a stranglehold on supplies of key products and ingredients.


That's especially critical in pharma. While a chip shortage may result in delays replacing a car or phone, a drug shortage delays treatments for controlling seizures, treating infections or managing severe pain, Brookings Institution senior fellow Marta Wosińska has noted.

In a report last year to Congress, the commission posed a hypothetical scenario in which Beijing withheld a breakthrough treatment from American patients in the event of a conflict in Taiwan.

State of play: Last month, the Trump administration proposed subjecting certain deals with Chinese life sciences companies to new screening requirements or prohibiting them altogether.


The commission, in its new analysis, calls the proposal "a prudent step to curtail China's biotechnology ambitions" but adds policymakers "must act now to empower the United States to out-innovate strategic competitors before it's too late."


There is no single percentage that captures global pharmaceutical production because the supply chain is sharply split between upstream raw ingredients (where China dominates) and downstream finished, high-value medicines (where the United States dominates).

Depending on which stage of production and which metric (volume vs. dollar value) you look at, the comparison flips completely:

Supply Chain Stage / Metric

China's Share

U.S. Share

Context & Notes

Key Starting Materials (KSMs) & Intermediates (Chemical building blocks)

~80% (of global intermediates)

< 10%

China is the world's primary supplier of the foundational chemical inputs used to make active ingredients.

Active Pharmaceutical Ingredients (APIs) (Share of total active FDA Drug Master Files)

18% (45% of new filings in 2024)

8% (3% of new filings in 2024)

India leads total active API filings (around 60%+), though Indian manufacturers rely on China for ~70–80% of their chemical inputs.

Finished Pharmaceutical Exports (By global dollar value, HS Code 30)

~1.6% – 2.2% ($14B–$20B)

~10% – 11% ($93B–$98B)

The U.S. exports high-value biologics, vaccines, and patented drugs; European nations (Germany, Switzerland, Ireland) account for the largest export shares.

Global Pharmaceutical Revenue / Market Value

~6% – 10%

~40% – 45%

The U.S. accounts for roughly $714B+ of the ~$1.7T–$1.8T global market, driven by high-margin branded therapies.

New Innovative Drug Pipeline (Share of global novel drugs developed)

~30%

~45% – 50%

While historically focused on generics and raw chemicals, China's share of newly developed innovative drugs surged to ~30% by 2025–2026.

Why the Numbers Look So Different

  1. China dominates volume and upstream chemistry:China specializes in the lower-margin, chemically intensive stages of manufacturing. It produces roughly 80% of the world's chemical intermediates and 71% of global antibiotic ingredients. Even when finished generic pills are stamped and packaged in India or Europe, the underlying active ingredients frequently originate in China.   

  2. The U.S. dominates value, biologics, and final formulation: The United States has largely exited small-molecule generic and API manufacturing (falling from 23% of global API capacity in the 1980s to under 8% today). Instead, U.S. manufacturing focuses on high-value finished drugs, complex biologics (grown in living cells rather than synthesized from chemicals), and sterile injectables—where the U.S. still leads global output. Because a single patented biologic can cost thousands of dollars per dose compared to pennies for generic chemical ingredients, the U.S. commands a massive share of global pharmaceutical dollar value despite producing a much smaller fraction of physical chemical tonnage.

 
 
 

Recent Posts

See All
Was Voldemort smart to meet with Putin and Xi?

Another jackass, Nixon, was the first US president to visit China in 1972. In retrospect a brilliant move and I believe history will look at the Dark Lord's move through a similar lens. Trump knocks

 
 
 
Is Extreme Poverty Is a Thing of the Past in India?

Bollywood! Where dreams become reality and poverty goes to die. Extreme Poverty Is a Thing of the Past in India Achieving prosperity will be a taller order. By Sadanand Dhume, WSJ Nov. 18, 2026 5:56 p

 
 
 

Comments


  • Facebook
  • Twitter
  • LinkedIn

©2021 by The Spritzler Report. Proudly created with Wix.com

bottom of page